Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | VP, Head of Accting;Controller | June 15, 2022 | June 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date June 15, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,583 |
Reported balance
After 2022-06-15 transaction · row 1
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 7,500 · Balance 13,583 F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs will vest on the earlier of (i) December 31, 2022, or (ii) the appointment of the Issuer's new Chief Financial Officer, subject to the Reporting Person's continued service to the Issuer as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs will vest on the earlier of (i) December 31, 2022, or (ii) the appointment of the Issuer's new Chief Financial Officer, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2022 Filed Jun 16, 2022 21:14 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037523 · doc4.xml · nonDerivative · entry 1 Makara Richard · CIK 0001798130 · VP, Head of Accting;Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,583 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs will vest on the earlier of (i) December 31, 2022, or (ii) the appointment of the Issuer's new Chief Financial Officer, subject to the Reporting Person's continued service to the Issuer as of such vesting date. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:12 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001209191-20-013111 · doc4.xml · derivative · entry 1 Makara Richard · CIK 0001798130 · VP, Head of Accting;Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-02-24 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 24, 2020, in each case subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.